|
Name |
Helicascolide A
|
Molecular Formula | C12H20O3 | |
IUPAC Name* |
(4R,5S,6S)-6-[(E)-but-2-en-2-yl]-4-hydroxy-3,3,5-trimethyloxan-2-one
|
|
SMILES |
C/C=C(\C)/[C@@H]1[C@H]([C@H](C(C(=O)O1)(C)C)O)C
|
|
InChI |
InChI=1S/C12H20O3/c1-6-7(2)9-8(3)10(13)12(4,5)11(14)15-9/h6,8-10,13H,1-5H3/b7-6+/t8-,9-,10-/m1/s1
|
|
InChIKey |
TXJOTIFCEKOXSM-BPESRRAMSA-N
|
|
Synonyms |
Helicascolide A; Helicascolide B; 121350-98-9; (4R,5S,6S)-6-[(E)-but-2-en-2-yl]-4-hydroxy-3,3,5-trimethyloxan-2-one; (4R,5S,6S)-Tetrahydro-4-hydroxy-3,3,5-trimethyl-6-[(E)-1-methyl-1-propenyl]-2H-pyran-2-one; 2H-Pyran-2-one, tetrahydro-4-hydroxy-3,3,5-trimethyl-6-(1-methyl-1-propenyl)-, (4alpha,5alpha,6beta(E))-(-)-
|
|
CAS | 121350-98-9 | |
PubChem CID | 6439087 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 212.28 | ALogp: | 2.5 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 46.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 15 | QED Weighted: | 0.536 |
Caco-2 Permeability: | -4.533 | MDCK Permeability: | 0.00004510 |
Pgp-inhibitor: | 0.07 | Pgp-substrate: | 0.024 |
Human Intestinal Absorption (HIA): | 0.026 | 20% Bioavailability (F20%): | 0.06 |
30% Bioavailability (F30%): | 0.18 |
Blood-Brain-Barrier Penetration (BBB): | 0.58 | Plasma Protein Binding (PPB): | 89.77% |
Volume Distribution (VD): | 1.154 | Fu: | 11.62% |
CYP1A2-inhibitor: | 0.112 | CYP1A2-substrate: | 0.291 |
CYP2C19-inhibitor: | 0.061 | CYP2C19-substrate: | 0.747 |
CYP2C9-inhibitor: | 0.026 | CYP2C9-substrate: | 0.615 |
CYP2D6-inhibitor: | 0.027 | CYP2D6-substrate: | 0.521 |
CYP3A4-inhibitor: | 0.03 | CYP3A4-substrate: | 0.34 |
Clearance (CL): | 9.263 | Half-life (T1/2): | 0.164 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.446 |
Drug-inuced Liver Injury (DILI): | 0.466 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.052 | Maximum Recommended Daily Dose: | 0.246 |
Skin Sensitization: | 0.206 | Carcinogencity: | 0.066 |
Eye Corrosion: | 0.174 | Eye Irritation: | 0.064 |
Respiratory Toxicity: | 0.225 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC006024 | 0.681 | D0E9KA | 0.224 | ||||
ENC004902 | 0.302 | D08BYK | 0.212 | ||||
ENC002880 | 0.294 | D0W2EK | 0.211 | ||||
ENC004901 | 0.286 | D0G6AB | 0.205 | ||||
ENC004129 | 0.270 | D04SFH | 0.205 | ||||
ENC003160 | 0.270 | D0P0HT | 0.196 | ||||
ENC005952 | 0.265 | D0D2TN | 0.194 | ||||
ENC005953 | 0.265 | D0H6VY | 0.194 | ||||
ENC003753 | 0.264 | D0K7LU | 0.192 | ||||
ENC002272 | 0.258 | D0I2SD | 0.191 |